Aurora Cannabis einfach TOP !!! (Seite 233)

[funcontainer]

Antwort auf Beitrag Nr.: 62.362.682 von checkpointuk am 13.01.20 19:51:51

Zitat von checkpointuk: Das sind die Anal-lysen die ich liebe. Dann sollte mein Einstieg doch noch von Erfolg gekrönnt sein

Manuel
Manuel ist Trader und Investor und seit mehr als 10 Jahren als Börsenjournalist aktiv. Er zeichnet sich durch kritische und tiefgründige Recherche aus und antizipiert Kursentwicklungen schneller als der durchschnittliche Börsianer.

[checkpointuk]

Antwort auf Beitrag Nr.: 62.362.553 von Roools am 13.01.20 19:40:38

Das sind die Anal-lysen die ich liebe. Dann sollte mein Einstieg doch noch von Erfolg gekrönnt sein

[funcontainer]

"Die Aktie von Aurora Cannabis (WKN: A12GS7) taumelt tiefer und tiefer. Heute fällt das Papier nach einem Analysten-Downgrade bis auf 1,50 US-Dollar."

... und steigt unter hohem Volumen über Vortagesschluß!

[Roools]

ACB:
https://www.sharedeals.de/aurora-cannabis-knallhartes-analys…

[checkpointuk]

Dito...danke 👍👍

[crackz]

Antwort auf Beitrag Nr.: 62.362.265 von checkpointuk am 13.01.20 19:20:18

Wünsche viel Glück 👍

[checkpointuk]

Bin auxh drin...und das zum höchsten Kurs heute...schauen wir mal...mich treibt wie immer die Charttechnik...zu 2 hab ich mich noch nicht getraut, nun schon 😄

[LuxuriaDoedl]

Kann auch schnell wieder abwärts gehen. Bin auch knapp unter 2 CAD rein, werd mir aber einen Stopp-Loss setzen.
Weiß auch nicht was heute die Canna-Werte treibt

[crackz]

Wo sind die Aurora Basher?

[funcontainer]

Mal was positives:

"The back story. Aurora Cannabis (ticker: ACB) stock has fallen nearly 76% in the past year, and 27% so far in 2020. Two analysts lowered their neutral ratings and price targets to $1 last week, noting concerns about the firm's ability to generate cash to pay off debt.
Aurora was down 4.2% to $1.58 on Monday morning while the S&P 500 index was up 0.4%. The ETFMG Alternative Harvest exchanged-traded fund (MJ), viewed as a de facto proxy for the pot industry, was up 2.5%.
One of the company's greenhouses appeared in an online sale listing, though the company clarified it was nonoperational and came with its acquisition of MedReleaf. The company said last month Chief Corporate Officer Cam Battley , one of the more public-facing executives in speaking with media and investors, was leaving the company.
Cantor Fitzergald analyst Pablo Zuanic wrote in a note earlier this month that strategic advisor Nelson Peltz should help the company find a chief executive officer who will bring greater financial discipline.
What's new. Zuanic wrote on Monday that the recent stock decline is a reaction to analyst downgrades and " misperceived matters."
"The CCO departure was good news, in our view; a planned asset sale is being done pretty much at book value; and debt covenants imply positive EBITDA by mid-year," he wrote.
He also argues trends have not worsened, noting conversations with management where they reaffirmed their prior outlook for the December quarter. They're also confident sales will ramp up in the second half of the fiscal year, with help from newly introduced cannabis derivative products like edibles and vapes.
"The CCO departure was good news, in our view; a planned asset sale is being done pretty much at book value; and debt covenants imply positive EBITDA by mid-year," he wrote.
He also argues trends have not worsened, noting conversations with management where they reaffirmed their prior outlook for the December quarter. They're also confident sales will ramp up in the second half of the fiscal year, with help from newly introduced cannabis derivative products like edibles and vapes.
"We would make use of the recent pullback (ACB -30% 30d vs. -10% for the group)," he wrote, referring to Canadian cannabis peers. "The poor liquidity makes the stock sensitive to downgrades (some done despite the absence of new catalysts/news) and misplaced market chatter."
Looking Ahead. Zuanic expects positive Ebitda by the June quarter, and operating expenses as a percentage of sales to start coming down.
His fiscal 2020 sales estimate of 338 million Canadian dollars ( US$259 million ) is well below consensus estimates at C$395 million , and is 32% lower than consensus for fiscal 2021. On the other hand, his adjusted Ebitda estimate is C$ 132 million for fiscal 2021, compared to consensus at C$77 million .
Excluding Canopy Growth (CGC) and Cronos Group (CRON), which have investors in big U.S. firms, Aurora deserves a premium to its average peers, given its improving cash flow picture, Zuanic says. Plus, he thinks a potential consumer packaged goods partner, or a well-known CEO, would drive upside.
Write to Connor Smith at [e-mail]